Results 61 to 70 of about 41,053 (230)

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

open access: yesAdvanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement   +12 more
wiley   +1 more source

A Novel Retinal Gene Therapy Strategy for Batten Disease and Beyond

open access: yesProceedings, 2020
Batten Disease is a fatal lysosomal storage disorder characterized by cognitive and [...]
Maura Schwartz   +7 more
doaj   +1 more source

Isolation Defines Identity: Functional Consequences of Extracellular Vesicle Purification Strategies

open access: yesAdvanced Healthcare Materials, EarlyView.
Four extracellular vesicle purification strategies are compared using ovarian‐cancer ascites and ES‐2 cell supernatants. A novel workflow links purification to function by combining particle‐normalized proteomics with matched cell‐free and cell‐based assays.
Christian Preußer   +10 more
wiley   +1 more source

Loss of Niemann-Pick C1 or C2 protein results in similar biochemical changes suggesting that these proteins function in a common lysosomal pathway. [PDF]

open access: yesPLoS ONE, 2011
Niemann-Pick Type C (NPC) disease is a lysosomal storage disorder characterized by accumulation of unesterified cholesterol and other lipids in the endolysosomal system.
Sayali S Dixit   +5 more
doaj   +1 more source

Engineered ETS1‐Nanoconjugate Restores Immune Homeostasis through Dual Immune‐Vascular Modulation in Relapsing and Progressive Multiple Sclerosis

open access: yesAdvanced Healthcare Materials, EarlyView.
The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang   +13 more
wiley   +1 more source

From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function

open access: yesAdvanced Healthcare Materials, EarlyView.
The evolution of lipid nanoparticles (LNPs) spans from RNA‐LNPs, used in mRNA vaccines, to DNA‐LNPs, ideal for gene therapies. Emerging bionano architectures, decorated with DNA and plasma proteins, pave the way for advanced DNA‐based therapies that are more stable, targeted, and customizable.
Erica Quagliarini   +2 more
wiley   +1 more source

Intrinsically Disordered Protein‐Inspired Nanovector‐Based Coacervates for the Direct Cytosolic Transport of Biomacromolecules

open access: yesAdvanced Materials, EarlyView.
Intrinsically disordered protein‐inspired nanovectors (IDP‐NVs) form stable nanocoacervates (NCs) with diverse biomacromolecules. In situ conformational changes confer stability and adaptability to NCs under dynamically changing physiological conditions.
Soyeong Jin   +14 more
wiley   +1 more source

Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases?

open access: yesMolecular Genetics and Metabolism Reports, 2017
Chronic intestinal pseudo-obstruction results in clinical manifestations that resemble intestinal obstruction but in the absence of any physical obstructive process.
J. Politei   +5 more
doaj   +1 more source

Tau accumulation in degradative organelles is associated to lysosomal stress

open access: yesScientific Reports, 2023
Neurodegenerative disorders are characterized by the brain deposition of insoluble amyloidogenic proteins, such as α-synuclein or Tau, and the concomitant deterioration of cell functions such as the autophagy-lysosomal pathway (ALP).
Ester Piovesana   +7 more
doaj   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

open access: yesAdvanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy